Nothing Special   »   [go: up one dir, main page]

CN102631553A - Medicament for treating reflux esophagitis - Google Patents

Medicament for treating reflux esophagitis Download PDF

Info

Publication number
CN102631553A
CN102631553A CN2012101312425A CN201210131242A CN102631553A CN 102631553 A CN102631553 A CN 102631553A CN 2012101312425 A CN2012101312425 A CN 2012101312425A CN 201210131242 A CN201210131242 A CN 201210131242A CN 102631553 A CN102631553 A CN 102631553A
Authority
CN
China
Prior art keywords
reflux esophagitis
rhizoma
radix
medicine
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012101312425A
Other languages
Chinese (zh)
Inventor
马守云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2012101312425A priority Critical patent/CN102631553A/en
Publication of CN102631553A publication Critical patent/CN102631553A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention belongs to the field of medicines, in particular to a medicament for treating reflux esophagitis, which is prepared from Chinese medicinal herbs of adenophora stricta, red-rooted salvia root, lignum dalbergiae odoriferae, syzygium aromaticum, cuttlebone, common bletilla tuber, fructus aurantii, pinellia ternate, three-nerved spicebush root, bighead atractylodes rhizome, coptis chinensis and the like. The medicament is prepared by adopting the following steps of: cleaning the Chinese medicinal herbs with clear water, uniformly mixing, adding water for decocting for 2-4 times and 1-2h for one time, mixing decoctions, filtering, concentrating filtrate to a clear paste with a temperature of 70 DEG C and a relative density of 1.15-1.18, refrigerating and standing, taking supernate and filtering, adding conventional excipients in the filtrate, uniformly mixing, adding purified water until the content of dried medicinal herbs is 1g/ml, canning, and sterilizing to prepare an oral liquid preparation. The medicament has the functions of relieving dyspepsia, clearing heat and removing stasis, promoting qi circulation and relieving pain, warming the kidney and dispelling cold, is high in effect taking speed for treating reflux esophagitis, ensures that inflammations rapidly disappear, has the effect of treating both principal and secondary aspect of diseases, and has the advantages of high cure rate, no relapse, no sequelae, and no pain of a patient in a treatment period.

Description

A kind of medicine of treating reflux esophagitis
Technical field
The invention belongs to drug world, being specifically related to a kind of is the medicine of the treatment reflux esophagitis of feedstock production with Chinese medicine.
Background technology
Reflux esophagitis is a kind of not multiple disease, but the harm people's health is very serious.Its reason is because the cold depression of liver-QI of insufficiency of stomach, disorder of stomach-QI, and gastric juice superinverse and causing stimulates esophagus to form the esophagus inflammation in the course of time.
Summary of the invention
The purpose of this invention is to provide a kind of medicine of treating reflux esophagitis, this medicine antiinflammatory detumescent, promoting blood circulation to restore menstrual flow, the heat clearing away eliminating stagnation, detumescence and apocenosis treatment acne cure rate is high, and relapse rate is low.
Medicine of the present invention is that crude drug prepares by following parts by weight of traditional Chinese medicines:
Radix Adenophorae (Radix Glehniae) 20-30 Radix Salviae Miltiorrhizaes 20-30
Lignum Dalbergiae Odoriferae 15-20 Flos Caryophyllis 6-12
Endoconcha Sepiae 12-15 Pseudobulbus Bletillae (Rhizoma Bletillae)s 12-15
Fructus Aurantii 13-16 Rhizoma Pinelliaes 8-10
The Radix Linderae 10-15 Rhizoma Atractylodis Macrocephalaes 10-15
Rhizoma Coptidis 6-9 Fructus Evodiaes 3-6
Rhizoma Cyperi 8-12 Squama Maniss 5-8
Radix Glycyrrhizae 6-8.
Can the above-mentioned raw materials medicine be processed any dosage form on the pharmaceutics, like tablet, pill, powder, capsule etc., the preferred dosage form of the present invention is an oral liquid.
The concrete method for preparing of above-mentioned each component being processed medicine of the present invention is:
With above-mentioned bulk drugs mix homogeneously, decocte with water 2-4 time, each 1-2 hour; Collecting decoction filters, and filtrating is condensed into the clear paste of 70 ℃ of relative density 1.15-1.18; Cold preservation is left standstill, and gets supernatant liquid filtering, adds conventional adjuvant in the filtrating; Mixing, adding purified water is 1g/mL to containing the crude drug amount, oral liquid formulations is processed in fill, sterilization.
Method for using: oral, each 1, every 15mL, every day 3 times.
In the prescription of the present invention, Radix Adenophorae (Radix Glehniae) clearing away heat and nourishing YIN, nourishing the lung to arrest cough; The Radix Salviae Miltiorrhizae promoting blood flow to regulate menstruation, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle, the relieving restlessness that clears away heart-fire, nourishing blood to tranquillize the mind; The Lignum Dalbergiae Odoriferae promoting flow of QI and blood, pain relieving, hemostasis; Flos Caryophylli warming middle-JIAO, warming the kidney, sending down the abnormal ascending QI; Skin ulcer is held back in Endoconcha Sepiae astringing to arrest bleeding, treating spontaneous emission and leukorrhagia, antacid; The Pseudobulbus Bletillae (Rhizoma Bletillae) has the effect of hemostasis tonifying the lung, granulation promoting pain relieving; Stop feeling of fullness distending pain, blocked-up chest in Fructus Aurantii is stagnant; Rhizoma Pinelliae master stomach is cold, the sound of vomiting of vomitting; Radix Linderae promoting the circulation of QI to relieve pain, warming kidney for dispelling cold; Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI, the dampness diuretic, hidroschesis, antiabortive; The Rhizoma Coptidis heat clearing and damp drying, eliminating fire and detoxication; Fructus Evodiae has the merit of heat radiation pain relieving, stopping nausea and vomiting by lowering the adverse flow of QI; The Rhizoma Cyperi resolving depression of regulating the flow of vital energy, menstruction regulating and pain relieving; The Squama Manis blood circulation promoting and dispersing pathogen accumulation, the stimulating milk secretion of stimulating the menstrual flow, eliminating carbuncle is burst hard; The Radix Glycyrrhizae invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.More than all medicines share, stop heat clearing away eliminating stagnation, promoting the circulation of QI to relieve pain, warming kidney for dispelling cold in stagnant; To the treatment reflux esophagitis, not only instant effect disappears inflammation fast, and has the effect of treating both the principal and secondary aspects of a disease; Cured substance rate of the present invention is high, does not recur no sequel, patient's no pain during the treatment.
For further investigating the clinical efficacy and the safety of medicine of the present invention, select 300 routine reflux esophagitis patients that the curative effect of medicine of the present invention is carried out clinical observation.
300 routine cases are divided into two groups at random, and 150 examples are organized in treatment, matched group 150 examples.All cases all meet the diagnostic criteria of reflux esophagitis in " Chinese GERD common recognition suggestion (in October, 2006 Sanya) ".
Diagnostic criteria:
1. typical heartburn and anti-stream symptom is arranged, do not have pyloric obstruction again or digestive tract blocks evidence;
2. mirror in the upper digestive tract: involve the esophagitis or the Barrett esophagus of far-end, and get rid of the insecondary causes of disease such as duodenal bulbar ulcer, pyloric obstruction, vomiting;
3. (PPI test) positive is tested in the proton pump inhibitor diagnostic treatment, and (standard metering PPI, every day 2 times, the course of treatment, 7-14d obviously improved as if symptom after taking medicine, and then positive is held in the relevant GERD of acid.);
4. esophagus 24h, the pH value monitoring is shown as the anti-stream of acid i.e. (Ph<4 total time >=4.0%).
More than four kinds of routine diagnosis standards meet 1 or 1+2 or 1+3 or 1+4 can be diagnosed as GERD.
Therapeutic Method:
The treatment group: use medicine of the present invention, oral, each 1, every 15mL, every day 3 times.
Matched group: take mosapride citrate sheet 5mg, every day 3 times, take before the meal.
Curative effect determinate standard:
Try 2002 formulation standards with reference to " new Chinese medicine clinical research guideline ":
Clinical recovery: tcm clinical practice symptom, sign disappear or basic the disappearance, and the syndrome integration reduces >=95%.
Produce effects: tcm clinical practice symptom, sign are obviously improved, and the syndrome integration reduces >=70%,<95%.
Effectively: tcm clinical practice symptom, sign all take a favorable turn, and the syndrome integration reduces >=30%,<70%.
Invalid: tcm clinical practice symptom, sign disappear all not have obviously and improve, even increase the weight of, the syndrome integration reduces less than 30%.Two groups of case treatment back curative effect comparative results are seen table 1.
Table 1 liang group case treatment back curative effect relatively
Group The example number Clinical recovery n (%) Produce effects n (%) Effective n (%) Invalid n (%) Total effective rate n (%)
Matched group 150 125(83.3) 8(5.3) 6(4) 11(7.4) 139(92.7)
The treatment group 150 140(93.3) 5(3.3) 4(2.7) 1(0.7) 149(99.3)
Clinical experiment is the result prove, drug effect of the present invention obviously is superior to matched group, do not see any untoward reaction.
The specific embodiment
Embodiment 1
Get Radix Adenophorae (Radix Glehniae) 30kg, Radix Salviae Miltiorrhizae 30 kg, Lignum Dalbergiae Odoriferae 20 kg, Flos Caryophylli 12 kg, Endoconcha Sepiae 15 kg, the Pseudobulbus Bletillae (Rhizoma Bletillae) 15 kg; Fructus Aurantii 16 kg, the Rhizoma Pinelliae 10 kg, the Radix Linderae 15 kg, the Rhizoma Atractylodis Macrocephalae 15 kg, Rhizoma Coptidis 9 kg, Fructus Evodiae 6 kg; Rhizoma Cyperi 12 kg, Squama Manis 8 kg, Radix Glycyrrhizae 8 kg clean above-mentioned medicaments in part by weight mix homogeneously, decocte with water 2-4 time with clear water; Each 1-2 hour, collecting decoction filtered, and filtrating is condensed into the clear paste of 70 ℃ of relative density 1.15-1.18, and cold preservation is left standstill; Get supernatant liquid filtering, add conventional adjuvant in the filtrating, mixing, adding purified water is 1g/mL to containing the crude drug amount, oral liquid formulations is processed in fill, sterilization.
Embodiment 2
Get Radix Adenophorae (Radix Glehniae) 20kg, Radix Salviae Miltiorrhizae 20 kg, Lignum Dalbergiae Odoriferae 15 kg, Flos Caryophylli 6 kg, Endoconcha Sepiae 12 kg, the Pseudobulbus Bletillae (Rhizoma Bletillae) 12 kg; Fructus Aurantii 13 kg, the Rhizoma Pinelliae 8 kg, the Radix Linderae 10 kg, the Rhizoma Atractylodis Macrocephalae 10 kg, Rhizoma Coptidis 6 kg, Fructus Evodiae 3 kg; Rhizoma Cyperi 8 kg, Squama Manis 5 kg, Radix Glycyrrhizae 6 kg clean above-mentioned medicaments in part by weight mix homogeneously, decocte with water 2-4 time with clear water; Each 1-2 hour, collecting decoction filtered, and filtrating is condensed into the clear paste of 70 ℃ of relative density 1.15-1.18, and cold preservation is left standstill; Get supernatant liquid filtering, add conventional adjuvant in the filtrating, mixing, adding purified water is 1g/mL to containing the crude drug amount, oral liquid formulations is processed in fill, sterilization.

Claims (3)

1. medicine of treating reflux esophagitis is that crude drug prepares by following parts by weight of traditional Chinese medicines:
Radix Adenophorae (Radix Glehniae) 20-30 Radix Salviae Miltiorrhizaes 20-30
Lignum Dalbergiae Odoriferae 15-20 Flos Caryophyllis 6-12
Endoconcha Sepiae 12-15 Pseudobulbus Bletillae (Rhizoma Bletillae)s 12-15
Fructus Aurantii 13-16 Rhizoma Pinelliaes 8-10
The Radix Linderae 10-15 Rhizoma Atractylodis Macrocephalaes 10-15
Rhizoma Coptidis 6-9 Fructus Evodiaes 3-6
Rhizoma Cyperi 8-12 Squama Maniss 5-8
Radix Glycyrrhizae 6-8.
2. the medicine of treatment reflux esophagitis according to claim 1 is characterized in that described medicine is processed oral liquid.
3. the method for preparing of the medicine of the said treatment reflux esophagitis of claim 2 is with above-mentioned bulk drugs mix homogeneously, decocte with water 2-4 time, each 1-2 hour; Collecting decoction filters, and filtrating is condensed into the clear paste of 70 ℃ of relative density 1.15-1.18; Cold preservation is left standstill, and gets supernatant liquid filtering, adds conventional adjuvant in the filtrating; Mixing, adding purified water is 1g/mL to containing the crude drug amount, oral liquid formulations is processed in fill, sterilization.
CN2012101312425A 2012-05-02 2012-05-02 Medicament for treating reflux esophagitis Pending CN102631553A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2012101312425A CN102631553A (en) 2012-05-02 2012-05-02 Medicament for treating reflux esophagitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2012101312425A CN102631553A (en) 2012-05-02 2012-05-02 Medicament for treating reflux esophagitis

Publications (1)

Publication Number Publication Date
CN102631553A true CN102631553A (en) 2012-08-15

Family

ID=46616234

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012101312425A Pending CN102631553A (en) 2012-05-02 2012-05-02 Medicament for treating reflux esophagitis

Country Status (1)

Country Link
CN (1) CN102631553A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103110913A (en) * 2013-02-15 2013-05-22 叶蕾 Preparation method of traditional Chinese medicine for treating qi-deficiency type reflux oesophagitis
CN104587238A (en) * 2014-12-24 2015-05-06 陈现忠 Traditional Chinese medicine formula for treating reflux esophagitis and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
匡淑美等: "中西医结合治疗返流性食管炎47例疗效观察", 《中国民间疗法》 *
顾立梅等: "反流性食管炎中医证治研究", 《吉林中医药》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103110913A (en) * 2013-02-15 2013-05-22 叶蕾 Preparation method of traditional Chinese medicine for treating qi-deficiency type reflux oesophagitis
CN104587238A (en) * 2014-12-24 2015-05-06 陈现忠 Traditional Chinese medicine formula for treating reflux esophagitis and preparation method thereof

Similar Documents

Publication Publication Date Title
CN102813702A (en) Lotion for treating rhinitis
CN102370949A (en) Chinese medicinal compound preparation for treating cholecystitis and preparation method thereof
CN100358571C (en) Hot compress plaster for treating mastosis and its preparing method
CN102614305A (en) Medicament for treating allergic purpura
CN101822780A (en) Medicament for treating oral ulcer and preparation method thereof
CN104001131B (en) A kind of Chinese medicine for oral administration preventing and treating stress ulcer
CN102631553A (en) Medicament for treating reflux esophagitis
CN103705900A (en) Traditional Chinese medicine composition for treating hypertension
CN101327293A (en) Capsules for treating peptic ulcer and preparation method thereof
CN103127417A (en) Drug for curing nasosinusitis and preparation method thereof
CN104173606A (en) Medicament for treating hemorrhoids
CN104547976A (en) Traditional Chinese medicinal composition for treating esophagus cancer
CN109528943A (en) A kind of formula of the highly enriched ball of anti influenza Chinese medicine and preparation
CN103520419B (en) Medicine for treating globus hysteriocus and preparation method thereof
CN103479948B (en) The anti-medicine treated constipation
CN101224295A (en) Chinese traditional medicine compounds for treating digestive system tumor and preparing method thereof
CN102018800A (en) Traditional Chinese medicinal preparation for treating heat type constipations
CN102100861A (en) Chinese medicine for treating children fever of unknown origin
CN108066406A (en) A kind of Chinese medicine for treating paediatric acute tonsillitis illness
CN105079580A (en) Traditional Chinese medicine composition for treating wind-warm lung-heat disease
CN105770571A (en) Medicament for treating epilepsy
CN105663850A (en) Traditional Chinese medicine composition for treating oral ulcer
CN106309960A (en) Traditional Chinese medicine composition for treating chronic gastric ulcer
CN105233162A (en) Traditional Chinese medicine composition for treating chronic cholecystitis, and preparation method and pharmaceuticals thereof
CN104435133A (en) Medicament for reducing fever

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120815